blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3434285

EP3434285 - COMBINATIONS OF OBETICHOLIC ACID AND EZETIMIBE FOR THE TREATMENT OF NAFLD AND NASH [Right-click to bookmark this link]
Former [2019/05]PHARMACEUTICAL COMPOSITION AND USE THEREOF
[2021/13]
StatusNo opposition filed within time limit
Status updated on  06.05.2022
Database last updated on 14.09.2024
FormerThe patent has been granted
Status updated on  28.05.2021
FormerGrant of patent is intended
Status updated on  18.03.2021
FormerExamination is in progress
Status updated on  07.08.2020
FormerRequest for examination was made
Status updated on  30.12.2018
FormerThe international publication has been made
Status updated on  29.09.2017
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024  [2024/29]
Applicant(s)For all designated states
Waterstone Pharmaceuticals (Wuhan) Co., Ltd.
B3-4 Biolake
No. 666 Gaoxin Road
Eastlake National High-Tech Development Zone
Wuhan, Hubei 430075 / CN
[2019/05]
Inventor(s)01 / LIU, Xiaoyu
B3-4 Biolake
No. 666 Gaoxin Road
Eastlake National High-Tech Development Zone
Wuhan Hubei 430075 / CN
02 / ZHANG, Faming
B3-4 Biolake
No. 666 Gaoxin Road
Eastlake National High-Tech Development Zone
Wuhan Hubei 430075 / CN
03 / CUI, Jian
B3-4 Biolake
No. 666 Gaoxin Road
Eastlake National High-Tech Development Zone
Wuhan Hubei 430075 / CN
04 / ZHANG, Sihan
B3-4 Biolake
No. 666 Gaoxin Road
Eastlake National High-Tech Development Zone
Wuhan Hubei 430075 / CN
05 / WANG, Huojian
B3-4 Biolake
No. 666 Gaoxin Road
Eastlake National High-Tech Development Zone
Wuhan Hubei 430075 / CN
06 / MENG, Yuan
B3-4 Biolake
No. 666 Gaoxin Road
Eastlake National High-Tech Development Zone
Wuhan Hubei 430075 / CN
07 / LENG, Zhengwen
B3-4 Biolake
No. 666 Gaoxin Road
Eastlake National High-Tech Development Zone
Wuhan Hubei 430075 / CN
08 / QIAN, Lina
B3-4 Biolake
No. 666 Gaoxin Road
Eastlake National High-Tech Development Zone
Wuhan Hubei 430075 / CN
 [2019/05]
Representative(s)Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[N/P]
Former [2019/05]Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Application number, filing date17769488.224.03.2017
[2019/05]
WO2017CN78183
Priority number, dateCN20161017331724.03.2016         Original published format: CN201610173317
[2019/05]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017162211
Date:28.09.2017
Language:ZH
[2017/39]
Type: A1 Application with search report 
No.:EP3434285
Date:30.01.2019
Language:EN
[2019/05]
Type: B1 Patent specification 
No.:EP3434285
Date:30.06.2021
Language:EN
[2021/26]
Search report(s)International search report - published on:CN28.09.2017
(Supplementary) European search report - dispatched on:EP26.09.2019
ClassificationIPC:A61K31/575, A61K31/397, A61K45/06, A61P1/16, A61P3/06, A61P3/10, A61P35/00, A61P43/00, A61P9/00
[2019/43]
CPC:
A61K31/397 (EP,CN,US); A61K45/06 (EP,CN,US); A61K31/575 (EP,CN,US);
A61P1/16 (EP,US); A61P3/06 (EP,US); A61P3/10 (EP,US);
A61P35/00 (EP,US); A61P43/00 (EP,US); A61P9/00 (EP,US);
A61K9/0053 (US) (-)
C-Set:
A61K31/397, A61K2300/00 (US,CN,EP);
A61K31/575, A61K2300/00 (CN,EP,US)
Former IPC [2019/05]A61K45/06, A61K31/575, A61K31/397, A61P1/16, A61P35/00, A61P3/06, A61P3/10, A61P9/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/05]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:ZUSAMMENSETZUNGEN AUS OBETICHOLSÄURE UND EZETIMIB ZUR BEHANDLUNG VON NAFLD UND NASH[2021/13]
English:COMBINATIONS OF OBETICHOLIC ACID AND EZETIMIBE FOR THE TREATMENT OF NAFLD AND NASH[2021/13]
French:COMBINAISONS DE L'ACIDE OBÉTICHOLIQUE ET DE L'EZETIMIBE DESTINÉES AU TRAITEMENT DE LA NAFLD ET DE LA NASH[2021/13]
Former [2019/05]PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND VERWENDUNG DAVON
Former [2019/05]PHARMACEUTICAL COMPOSITION AND USE THEREOF
Former [2019/05]COMPOSITION PHARMACEUTIQUE ET SES UTILISATIONS
Entry into regional phase27.09.2018Translation filed 
27.09.2018National basic fee paid 
27.09.2018Search fee paid 
27.09.2018Designation fee(s) paid 
27.09.2018Examination fee paid 
Examination proceduredeletedDate on which the examining division has become responsible
27.09.2018Examination requested  [2019/05]
30.12.2019Amendment by applicant (claims and/or description)
11.08.2020Despatch of a communication from the examining division (Time limit: M04)
29.10.2020Reply to a communication from the examining division
19.03.2021Communication of intention to grant the patent
20.05.2021Fee for grant paid
20.05.2021Fee for publishing/printing paid
20.05.2021Receipt of the translation of the claim(s)
Opposition(s)31.03.2022No opposition filed within time limit [2022/23]
Fees paidRenewal fee
26.02.2019Renewal fee patent year 03
30.03.2020Renewal fee patent year 04
23.02.2021Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU24.03.2017
AL30.06.2021
AT30.06.2021
CY30.06.2021
CZ30.06.2021
DK30.06.2021
EE30.06.2021
ES30.06.2021
FI30.06.2021
HR30.06.2021
IT30.06.2021
LT30.06.2021
LV30.06.2021
MC30.06.2021
MK30.06.2021
NL30.06.2021
PL30.06.2021
RO30.06.2021
RS30.06.2021
SE30.06.2021
SI30.06.2021
SK30.06.2021
SM30.06.2021
TR30.06.2021
BG30.09.2021
NO30.09.2021
GR01.10.2021
IS30.10.2021
PT02.11.2021
LU24.03.2022
[2024/29]
Former [2024/23]HU24.03.2017
AL30.06.2021
AT30.06.2021
CY30.06.2021
CZ30.06.2021
DK30.06.2021
EE30.06.2021
ES30.06.2021
FI30.06.2021
HR30.06.2021
IT30.06.2021
LT30.06.2021
LV30.06.2021
MC30.06.2021
MK30.06.2021
NL30.06.2021
PL30.06.2021
RO30.06.2021
RS30.06.2021
SE30.06.2021
SI30.06.2021
SK30.06.2021
SM30.06.2021
BG30.09.2021
NO30.09.2021
GR01.10.2021
IS30.10.2021
PT02.11.2021
LU24.03.2022
Former [2024/20]HU24.03.2017
AL30.06.2021
AT30.06.2021
CY30.06.2021
CZ30.06.2021
DK30.06.2021
EE30.06.2021
ES30.06.2021
FI30.06.2021
HR30.06.2021
IT30.06.2021
LT30.06.2021
LV30.06.2021
MC30.06.2021
NL30.06.2021
PL30.06.2021
RO30.06.2021
RS30.06.2021
SE30.06.2021
SI30.06.2021
SK30.06.2021
SM30.06.2021
BG30.09.2021
NO30.09.2021
GR01.10.2021
IS30.10.2021
PT02.11.2021
LU24.03.2022
Former [2024/18]HU24.03.2017
AL30.06.2021
AT30.06.2021
CZ30.06.2021
DK30.06.2021
EE30.06.2021
ES30.06.2021
FI30.06.2021
HR30.06.2021
IT30.06.2021
LT30.06.2021
LV30.06.2021
MC30.06.2021
NL30.06.2021
PL30.06.2021
RO30.06.2021
RS30.06.2021
SE30.06.2021
SI30.06.2021
SK30.06.2021
SM30.06.2021
BG30.09.2021
NO30.09.2021
GR01.10.2021
IS30.10.2021
PT02.11.2021
LU24.03.2022
Former [2023/19]AL30.06.2021
AT30.06.2021
CZ30.06.2021
DK30.06.2021
EE30.06.2021
ES30.06.2021
FI30.06.2021
HR30.06.2021
IT30.06.2021
LT30.06.2021
LV30.06.2021
MC30.06.2021
NL30.06.2021
PL30.06.2021
RO30.06.2021
RS30.06.2021
SE30.06.2021
SI30.06.2021
SK30.06.2021
SM30.06.2021
BG30.09.2021
NO30.09.2021
GR01.10.2021
IS30.10.2021
PT02.11.2021
LU24.03.2022
Former [2023/08]AL30.06.2021
AT30.06.2021
CZ30.06.2021
DK30.06.2021
EE30.06.2021
ES30.06.2021
FI30.06.2021
HR30.06.2021
IT30.06.2021
LV30.06.2021
MC30.06.2021
NL30.06.2021
PL30.06.2021
RO30.06.2021
RS30.06.2021
SE30.06.2021
SI30.06.2021
SK30.06.2021
SM30.06.2021
BG30.09.2021
NO30.09.2021
GR01.10.2021
IS30.10.2021
PT02.11.2021
LU24.03.2022
Former [2022/47]AL30.06.2021
AT30.06.2021
CZ30.06.2021
DK30.06.2021
EE30.06.2021
ES30.06.2021
FI30.06.2021
HR30.06.2021
IT30.06.2021
LV30.06.2021
MC30.06.2021
NL30.06.2021
PL30.06.2021
RO30.06.2021
RS30.06.2021
SE30.06.2021
SI30.06.2021
SK30.06.2021
SM30.06.2021
BG30.09.2021
NO30.09.2021
GR01.10.2021
IS30.10.2021
PT02.11.2021
Former [2022/36]AL30.06.2021
AT30.06.2021
CZ30.06.2021
DK30.06.2021
EE30.06.2021
ES30.06.2021
FI30.06.2021
HR30.06.2021
IT30.06.2021
LV30.06.2021
NL30.06.2021
PL30.06.2021
RO30.06.2021
RS30.06.2021
SE30.06.2021
SI30.06.2021
SK30.06.2021
SM30.06.2021
BG30.09.2021
NO30.09.2021
GR01.10.2021
IS30.10.2021
PT02.11.2021
Former [2022/29]AL30.06.2021
AT30.06.2021
CZ30.06.2021
DK30.06.2021
EE30.06.2021
ES30.06.2021
FI30.06.2021
HR30.06.2021
LV30.06.2021
NL30.06.2021
PL30.06.2021
RO30.06.2021
RS30.06.2021
SE30.06.2021
SI30.06.2021
SK30.06.2021
SM30.06.2021
BG30.09.2021
NO30.09.2021
GR01.10.2021
IS30.10.2021
PT02.11.2021
Former [2022/26]AL30.06.2021
AT30.06.2021
CZ30.06.2021
DK30.06.2021
EE30.06.2021
ES30.06.2021
FI30.06.2021
HR30.06.2021
LV30.06.2021
NL30.06.2021
PL30.06.2021
RO30.06.2021
RS30.06.2021
SE30.06.2021
SK30.06.2021
SM30.06.2021
BG30.09.2021
NO30.09.2021
GR01.10.2021
IS30.10.2021
PT02.11.2021
Former [2022/21]AT30.06.2021
CZ30.06.2021
DK30.06.2021
EE30.06.2021
ES30.06.2021
FI30.06.2021
HR30.06.2021
LV30.06.2021
NL30.06.2021
PL30.06.2021
RO30.06.2021
RS30.06.2021
SE30.06.2021
SK30.06.2021
SM30.06.2021
BG30.09.2021
NO30.09.2021
GR01.10.2021
IS30.10.2021
PT02.11.2021
Former [2022/10]AT30.06.2021
CZ30.06.2021
EE30.06.2021
ES30.06.2021
FI30.06.2021
HR30.06.2021
LV30.06.2021
NL30.06.2021
PL30.06.2021
RO30.06.2021
RS30.06.2021
SE30.06.2021
SK30.06.2021
SM30.06.2021
BG30.09.2021
NO30.09.2021
GR01.10.2021
IS30.10.2021
PT02.11.2021
Former [2022/09]AT30.06.2021
CZ30.06.2021
ES30.06.2021
FI30.06.2021
HR30.06.2021
LV30.06.2021
NL30.06.2021
RO30.06.2021
RS30.06.2021
SE30.06.2021
SK30.06.2021
SM30.06.2021
BG30.09.2021
NO30.09.2021
GR01.10.2021
PT02.11.2021
Former [2022/08]AT30.06.2021
CZ30.06.2021
ES30.06.2021
FI30.06.2021
HR30.06.2021
LV30.06.2021
NL30.06.2021
RS30.06.2021
SE30.06.2021
SM30.06.2021
BG30.09.2021
NO30.09.2021
GR01.10.2021
Former [2022/07]AT30.06.2021
FI30.06.2021
HR30.06.2021
LV30.06.2021
NL30.06.2021
RS30.06.2021
SE30.06.2021
SM30.06.2021
BG30.09.2021
NO30.09.2021
GR01.10.2021
Former [2021/51]FI30.06.2021
HR30.06.2021
LV30.06.2021
RS30.06.2021
SE30.06.2021
BG30.09.2021
NO30.09.2021
GR01.10.2021
Former [2021/49]FI30.06.2021
HR30.06.2021
LV30.06.2021
SE30.06.2021
BG30.09.2021
NO30.09.2021
GR01.10.2021
Former [2021/47]FI30.06.2021
BG30.09.2021
Former [2021/46]FI30.06.2021
Documents cited:Search[XI]RU2473342  ;
 [XPI]CN105748487  ;
 [XI]  - DATABASE WPI, 0, Derwent World Patents Index, vol. 2013, no. 30, Database accession no. 2013-B77345, XP002794127 & RU2473342 C1 20130127 (CHERKASHOVA E A) [X] 1-9,13,14 * abstract * [I] 1-14
 [XPI]  - DATABASE WPI, 0, Derwent World Patents Index, vol. 2016, no. 82, Database accession no. 2016-47093V, XP002794128 & CN105748487 A 20160713 (WATERSTONE BIOMEDICAL TECHNOLOGY WUHAN) [XP] 1-9,13,14 * abstract * [I] 1-14
 [Y]  - SUNDER MUDALIAR ET AL, "Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease", GASTROENTEROLOGY, (20130901), vol. 145, no. 3, doi:10.1053/j.gastro.2013.05.042, ISSN 0016-5085, pages 574 - 582.e1, XP055086786 [Y] 1-14 * abstract * * page 581, column 1, line 10 - line 13 *

DOI:   http://dx.doi.org/10.1053/j.gastro.2013.05.042
 [Y]  - YUMIE TAKESHITA ET AL, "The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial", DIABETOLOGIA, BERLIN, DE, (20140110), vol. 57, no. 5, doi:10.1007/s00125-013-3149-9, ISSN 0012-186X, pages 878 - 890, XP055620521 [Y] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1007/s00125-013-3149-9
International search[A]CN102451161  (LIYAN WANG) [A] 1-14 * , the whole document *;
 [A]  - LI , PEIFENG, "Studies on Mechanism of Antiasthmatic and Anti-Inflammatory Actions of CDCA", CHINA JOURNAL OF CHINESE MATERIA MEDICA, (20040430), vol. 29, no. 4, ISSN 1001-5302, pages 349 - 352, XP009512534 [A] 1-14
 [A]  - LIAO, XIANHUA et al., "Advances and Prognosis in the Treatment of Non-Alcoholic Fatty Liver Disease", Ganzang = CHINESE HEPATOLOGY, (20120430), vol. 17, no. 4, pages 280 - 283, XP009514074 [A] 1-14
 [A]  - SU , YU et al., "Lipid-Lowering and Pleiotropic Effects of Ezetimibe Co-Administration", CHINESE JOURNAL OF NEW DRUGS, (20100831), vol. 19, no. 8, pages 666 - 670, XP9513300 [A] 1-14
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.